{"id":56879,"date":"2026-02-11T21:11:28","date_gmt":"2026-02-11T13:11:28","guid":{"rendered":"https:\/\/flcube.com\/?p=56879"},"modified":"2026-02-11T21:11:29","modified_gmt":"2026-02-11T13:11:29","slug":"eli-lillys-omvoh-wins-nmpa-approval-for-crohns-disease-and-ulcerative-colitis-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56879","title":{"rendered":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China"},"content":{"rendered":"\n

The National Medical Products Administration (NMPA)<\/strong> has approved Eli Lilly and Company\u2019s<\/strong> (NYSE:\u202fLLY<\/a><\/strong>) Omvoh (mirikizumab)<\/strong>, an interleukin-23 p19 antagonist<\/strong>, for the treatment of moderately to severely active Crohn\u2019s disease (CD)<\/strong> and ulcerative colitis (UC)<\/strong> in adult patients<\/strong>. The IgG4 monoclonal antibody<\/strong>, first approved in the US in 2023<\/strong>, becomes the first IL-23 p19 inhibitor<\/strong> cleared for both inflammatory bowel disease indications<\/strong> in China, challenging Johnson & Johnson\u2019s Stelara<\/strong> and AbbVie\u2019s Skyrizi<\/strong> in the rapidly expanding biologics market<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Eli Lilly and Company (NYSE:\u202fLLY)<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Omvoh (mirikizumab) \u2013 IL-23 p19 antagonist<\/td><\/tr>
Drug Class<\/strong><\/td>IgG4 monoclonal antibody<\/td><\/tr>
Approved Indications<\/strong><\/td>Moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC)<\/td><\/tr>
Global Approvals<\/strong><\/td>US (2023), EU, Japan, and others<\/td><\/tr>
Mechanism<\/strong><\/td>Selective IL-23 p19 subunit inhibition; immune-inflammatory modulation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence Summary<\/h2>\n\n\n\n
Study<\/th>Indication<\/th>Key Outcomes<\/th>Clinical Significance<\/th><\/tr><\/thead>
VIVID-1 (Phase III)<\/strong><\/td>Crohn\u2019s disease<\/td>Significantly improved clinical remission and endoscopic response<\/strong> at one year vs. placebo<\/td>First-line biologic efficacy in luminal CD<\/td><\/tr>
LUCENT (Phase III)<\/strong><\/td>Ulcerative colitis<\/td>Achieved primary and key secondary endpoints<\/strong>; sustained clinical remission; significantly alleviated bowel urgency<\/strong><\/td>Rapid symptom control; quality-of-life improvement<\/td><\/tr>
Safety Profile<\/strong><\/td>Both indications<\/td>Favorable tolerability<\/strong> across studies<\/td>Competitive safety vs. anti-TNF and JAK inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China IBD Market<\/strong><\/td>>1.5 million IBD patients<\/strong>; biologic penetration <15% vs. >50% in US\/EU; massive growth runway<\/td><\/tr>
IL-23 Class Competition<\/strong><\/td>Stelara (J&J)<\/strong> \u2013 IL-12\/23 approved for CD\/UC; Skyrizi (AbbVie)<\/strong> \u2013 IL-23 p19 approved for CD (UC pending)<\/td><\/tr>
Differentiation vs. Anti-TNF<\/strong><\/td>IL-23 selectivity avoids TNF-related immunogenicity<\/strong> and secondary loss of response<\/strong>; convenient dosing (every 4-8 weeks)<\/td><\/tr>
Eli Lilly China Strategy<\/strong><\/td>Omvoh joins Mounjaro\/Zepbound (tirzepatide)<\/strong> and Verzenio (abemaciclib)<\/strong> in high-growth therapeutic franchises<\/strong>; leverages established immunology sales force<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Commercial & Reimbursement Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
Launch<\/strong><\/td>Hospital formulary access in tier-1\/2 cities; gastroenterology specialist education<\/td>Q1-Q2\u202f2026<\/td><\/tr>
NRDL Negotiation<\/strong><\/td>National Reimbursement Drug List inclusion for CD\/UC<\/td>2026-2027<\/td><\/tr>
Market Share Capture<\/strong><\/td>Position as first-line biologic<\/strong> in anti-TNF failures and biologic-na\u00efve<\/strong> patients<\/td>2026-2028<\/td><\/tr>
Combination Strategy<\/strong><\/td>Explore Omvoh + JAK inhibitors or biosimilars in refractory IBD<\/td>Investigational<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Omvoh commercial launch timelines in China, NRDL pricing and reimbursement outcomes, and competitive dynamics with J&J Stelara and AbbVie Skyrizi. Actual results may differ due to NMPA post-marketing requirements, hospital procurement delays, and physician adoption curves for novel biologics in IBD.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab),…<\/p>\n","protected":false},"author":1,"featured_media":56880,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,911,15],"class_list":["post-56879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eli-lilly","tag-nyse-lly","tag-product-approvals"],"yoast_head":"\nEli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab), an interleukin-23 p19 antagonist, for the treatment of moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC) in adult patients. The IgG4 monoclonal antibody, first approved in the US in 2023, becomes the first IL-23 p19 inhibitor cleared for both inflammatory bowel disease indications in China, challenging Johnson & Johnson\u2019s Stelara and AbbVie\u2019s Skyrizi in the rapidly expanding biologics market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56879\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab), an interleukin-23 p19 antagonist, for the treatment of moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC) in adult patients. The IgG4 monoclonal antibody, first approved in the US in 2023, becomes the first IL-23 p19 inhibitor cleared for both inflammatory bowel disease indications in China, challenging Johnson & Johnson\u2019s Stelara and AbbVie\u2019s Skyrizi in the rapidly expanding biologics market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56879\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T13:11:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T13:11:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China\",\"datePublished\":\"2026-02-11T13:11:28+00:00\",\"dateModified\":\"2026-02-11T13:11:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1101.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56879#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56879\",\"name\":\"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1101.webp\",\"datePublished\":\"2026-02-11T13:11:28+00:00\",\"dateModified\":\"2026-02-11T13:11:29+00:00\",\"description\":\"The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab), an interleukin-23 p19 antagonist, for the treatment of moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC) in adult patients. The IgG4 monoclonal antibody, first approved in the US in 2023, becomes the first IL-23 p19 inhibitor cleared for both inflammatory bowel disease indications in China, challenging Johnson & Johnson\u2019s Stelara and AbbVie\u2019s Skyrizi in the rapidly expanding biologics market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56879\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56879#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab), an interleukin-23 p19 antagonist, for the treatment of moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC) in adult patients. The IgG4 monoclonal antibody, first approved in the US in 2023, becomes the first IL-23 p19 inhibitor cleared for both inflammatory bowel disease indications in China, challenging Johnson & Johnson\u2019s Stelara and AbbVie\u2019s Skyrizi in the rapidly expanding biologics market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56879","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China","og_description":"The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab), an interleukin-23 p19 antagonist, for the treatment of moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC) in adult patients. The IgG4 monoclonal antibody, first approved in the US in 2023, becomes the first IL-23 p19 inhibitor cleared for both inflammatory bowel disease indications in China, challenging Johnson & Johnson\u2019s Stelara and AbbVie\u2019s Skyrizi in the rapidly expanding biologics market.","og_url":"https:\/\/flcube.com\/?p=56879","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T13:11:28+00:00","article_modified_time":"2026-02-11T13:11:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56879#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56879"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China","datePublished":"2026-02-11T13:11:28+00:00","dateModified":"2026-02-11T13:11:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56879"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp","keywords":["Eli Lilly","NYSE: LLY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56879#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56879","url":"https:\/\/flcube.com\/?p=56879","name":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56879#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp","datePublished":"2026-02-11T13:11:28+00:00","dateModified":"2026-02-11T13:11:29+00:00","description":"The National Medical Products Administration (NMPA) has approved Eli Lilly and Company\u2019s (NYSE:\u202fLLY) Omvoh (mirikizumab), an interleukin-23 p19 antagonist, for the treatment of moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC) in adult patients. The IgG4 monoclonal antibody, first approved in the US in 2023, becomes the first IL-23 p19 inhibitor cleared for both inflammatory bowel disease indications in China, challenging Johnson & Johnson\u2019s Stelara and AbbVie\u2019s Skyrizi in the rapidly expanding biologics market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56879#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56879"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56879#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp","width":1080,"height":608,"caption":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56879#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly\u2019s Omvoh Wins NMPA Approval for Crohn\u2019s Disease and Ulcerative Colitis in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56879"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56879\/revisions"}],"predecessor-version":[{"id":56881,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56879\/revisions\/56881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56880"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}